The government’s internal inter-agency machinery does the heavy lifting before industry is invited in. That upstream process shapes, narrows and will almost certainly set the terms under which any negotiation involving the industry can take place. It still creates opportunity.
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australians want more from healthcare as convenience, prevention and fragmentation reshape care
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Neurizon secures GMP supply of monepantel to strengthen NUZ 001 commercial readiness
June 17, 2026 - - Australian Biotech -
Percheron completes HMBD-002 drug substance manufacture
June 17, 2026 - - Australian Biotech -
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 - - Australian Biotech -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News

